Dark | Light
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

# ![@Perspective_Tx Avatar](https://lunarcrush.com/gi/w:26/cr:twitter::1684919119819251712.png) @Perspective_Tx Perspective Therapeutics

Perspective Therapeutics posts on X about $catx, has been, germany, cest the most. They currently have XXX followers and XX posts still getting attention that total XXX engagements in the last XX hours.

### Engagements: XXX [#](/creator/twitter::1684919119819251712/interactions)
![Engagements Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1684919119819251712/c:line/m:interactions.svg)

- X Week XXX +248%
- X Month XXXXX +430%
- X Months XXXXX +126%
- X Year XXXXX +958%

### Mentions: X [#](/creator/twitter::1684919119819251712/posts_active)
![Mentions Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1684919119819251712/c:line/m:posts_active.svg)


### Followers: XXX [#](/creator/twitter::1684919119819251712/followers)
![Followers Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1684919119819251712/c:line/m:followers.svg)

- X Week XXX +4.70%
- X Month XXX +9.80%
- X Months XXX +38%
- X Year XXX +60%

### CreatorRank: XXXXXXXXX [#](/creator/twitter::1684919119819251712/influencer_rank)
![CreatorRank Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1684919119819251712/c:line/m:influencer_rank.svg)

### Social Influence [#](/creator/twitter::1684919119819251712/influence)
---

**Social category influence**
[countries](/list/countries) 

**Social topic influence**
[$catx](/topic/$catx) #2, [has been](/topic/has-been), [germany](/topic/germany), [cest](/topic/cest)
### Top Social Posts [#](/creator/twitter::1684919119819251712/posts)
---
Top posts by engagements in the last XX hours

"Were proud to be featured in @PharmaNowGlobal highlighting the first patient has been dosed in a new cohort of our Phase 1/2a trial exploring 212PbVMT01 in combination with a PD-1 inhibitor. For more details: $CATX #TargetedAlphaTherapy #oncology"  
[X Link](https://x.com/Perspective_Tx/status/1976395024179888295) [@Perspective_Tx](/creator/x/Perspective_Tx) 2025-10-09T21:11Z XXX followers, XXX engagements


"We are on the ground at the European Society for Medical Oncology Congress 2025 (#ESMO25) in Berlin Germany We will be presenting updated interim results from our Phase 1/2a study of 212PbVMT--NET on Monday Oct. XX at 8:58AM CEST. For more: $CATX"  
[X Link](https://x.com/Perspective_Tx/status/1979995998479880556) [@Perspective_Tx](/creator/x/Perspective_Tx) 2025-10-19T19:40Z XXX followers, XXX engagements


"Earlier today Perspective presented updated interim results from its Phase 1/2a study of 212PbVMT--NET at #ESMO25. There will be a conference call today to discuss the data at 8:30AM ET. For more details on the presentation and conference call: $CATX"  
[X Link](https://x.com/Perspective_Tx/status/1980236379188769246) [@Perspective_Tx](/creator/x/Perspective_Tx) 2025-10-20T11:35Z XXX followers, XXX engagements

[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

@Perspective_Tx Avatar @Perspective_Tx Perspective Therapeutics

Perspective Therapeutics posts on X about $catx, has been, germany, cest the most. They currently have XXX followers and XX posts still getting attention that total XXX engagements in the last XX hours.

Engagements: XXX #

Engagements Line Chart

  • X Week XXX +248%
  • X Month XXXXX +430%
  • X Months XXXXX +126%
  • X Year XXXXX +958%

Mentions: X #

Mentions Line Chart

Followers: XXX #

Followers Line Chart

  • X Week XXX +4.70%
  • X Month XXX +9.80%
  • X Months XXX +38%
  • X Year XXX +60%

CreatorRank: XXXXXXXXX #

CreatorRank Line Chart

Social Influence #


Social category influence countries

Social topic influence $catx #2, has been, germany, cest

Top Social Posts #


Top posts by engagements in the last XX hours

"Were proud to be featured in @PharmaNowGlobal highlighting the first patient has been dosed in a new cohort of our Phase 1/2a trial exploring 212PbVMT01 in combination with a PD-1 inhibitor. For more details: $CATX #TargetedAlphaTherapy #oncology"
X Link @Perspective_Tx 2025-10-09T21:11Z XXX followers, XXX engagements

"We are on the ground at the European Society for Medical Oncology Congress 2025 (#ESMO25) in Berlin Germany We will be presenting updated interim results from our Phase 1/2a study of 212PbVMT--NET on Monday Oct. XX at 8:58AM CEST. For more: $CATX"
X Link @Perspective_Tx 2025-10-19T19:40Z XXX followers, XXX engagements

"Earlier today Perspective presented updated interim results from its Phase 1/2a study of 212PbVMT--NET at #ESMO25. There will be a conference call today to discuss the data at 8:30AM ET. For more details on the presentation and conference call: $CATX"
X Link @Perspective_Tx 2025-10-20T11:35Z XXX followers, XXX engagements

creator/x::Perspective_Tx
/creator/x::Perspective_Tx